RNTX Rein Therapeutics, Inc. Common Stock

$RNTX Within the span of 24–48 hours, the competitive landscape for next-generation IPF therapies saw: 1) Bristol Myers Squibb (BMY): Delivered confusing, non-linear Phase 3 dose data on their oral LPA1 antagonist. 2) Syndax (SNDX): Completely shut down their Phase 2 IPF pipeline asset. For a micro-cap biotech like Rein Therapeutics, every high-profile trial failure or mixed result from larger competitors clears potential clutter from the future market. If LTI-03’s ongoing Phase 2 RENEW trial delivers clean safety and clear FVC preservation in its upcoming interim readouts, Rein will stand out even further as one of the few biotechs with a viable, disease-modifying, inhaled asset in a multi-billion dollar market.

$RNTX If we have good data the BMY mixed data bodes well for us. With respect to anything IPF it's known as a drug graveyard because nothing seems to work. So, based on the history in this space and the share price it's assumed RNTX is a failure also.

$RNTX It would be kind of wierd to not using social media to get the message out for free.

$RNTX it’s kind of weird to have IR here on the chat board Not something I want personally

$RNTX im not in yet. They have cash on hand. iPf interim data due 2nd half of 2026- which is anytime now. Nice institutional ownership Backburner play

When we talk about “regeneration” in IPF, we’re really talking about preserving the lung’s own ability to repair itself. In this short video, I explain why type 2 epithelial cells matter, and why supporting those cells is an important part of the LTI-03 approach. $RNTX

$RNTX someone is exiting a large position here. Hopefully its just a margin call and nothing else

$RNTX I’m in for 30k shares as a starter today. I’ll add another 30-40k slowly over the next week or so. I think this has potential to move.

One of the simplest questions in IPF is also one of the most important: Does the lung keep working? Our CSO, Cory Hogaboam, has spent more than 25 years studying lung fibrosis. In this short video, he explains how he thinks about lung function, FVC, and what we ultimately hope to learn from our Phase 2 RENEW trial. $RNTX